Published in N Engl J Med on June 21, 2007
A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early (SAVE) | NCT02741999
Screening to Improve Survival in AL Amyloidosis | NCT04615572
Multiple myeloma. Blood (2008) 5.88
A monoclonal gammopathy precedes multiple myeloma in most patients. Blood (2009) 3.98
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Treatment of multiple myeloma. Nat Rev Clin Oncol (2011) 2.46
IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol (2010) 2.35
Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park) (2011) 2.21
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood (2013) 1.98
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc (2009) 1.96
Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev (2010) 1.96
Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma (2009) 1.63
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A (2008) 1.59
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia (2013) 1.54
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia (2013) 1.51
Diagnosis of smoldering multiple myeloma. N Engl J Med (2011) 1.42
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia (2012) 1.41
Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med (2011) 1.35
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol (2012) 1.35
Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol (2009) 1.32
Curing myeloma at last: defining criteria and providing the evidence. Blood (2014) 1.30
Treatment of newly diagnosed myeloma. Leukemia (2008) 1.27
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia (2012) 1.27
Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer (2012) 1.27
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica (2009) 1.19
Haematological cancer: Redefining myeloma. Nat Rev Clin Oncol (2012) 1.17
Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc (2010) 1.11
Smoldering multiple myeloma requiring treatment: time for a new definition? Blood (2013) 1.09
Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc (2016) 1.07
Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood (2012) 1.06
Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica (2009) 1.05
Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood (2015) 1.04
Smoldering multiple myeloma. Blood (2015) 1.03
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia (2012) 0.99
Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma (2011) 0.97
The genetic architecture of multiple myeloma. Adv Hematol (2014) 0.96
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res (2012) 0.96
Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin Med Insights Oncol (2013) 0.95
Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica (2009) 0.95
Haematological cancer: Treatment of smoldering multiple myeloma. Nat Rev Clin Oncol (2013) 0.95
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2016) 0.94
Myeloma today: Disease definitions and treatment advances. Am J Hematol (2016) 0.94
Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. Mayo Clin Proc (2009) 0.92
Genomic analysis of high-risk smoldering multiple myeloma. Haematologica (2012) 0.90
Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model. Oncotarget (2014) 0.89
How I treat smoldering multiple myeloma. Blood (2014) 0.89
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia (2015) 0.86
Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol (2014) 0.86
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am J Hematol (2010) 0.85
Meeting report: Spontaneous lesions and diseases in wild, captive-bred, and zoo-housed nonhuman primates and in nonhuman primate species used in drug safety studies. Vet Pathol (2012) 0.85
Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J (2015) 0.85
The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia (2014) 0.85
C-src enriched serum microvesicles are generated in malignant plasma cell dyscrasia. PLoS One (2013) 0.84
Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn (2011) 0.84
Deep Response in Multiple Myeloma: A Critical Review. Biomed Res Int (2015) 0.84
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. Br J Haematol (2009) 0.83
Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma. Mayo Clin Proc (2010) 0.83
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Curr Hematol Malig Rep (2010) 0.82
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica (2015) 0.82
Dilemmas in treating smoldering multiple myeloma. J Clin Oncol (2014) 0.81
Staging and prognostication of multiple myeloma. Expert Rev Hematol (2014) 0.81
Does my patient with a serum monoclonal spike have multiple myeloma? Hematol Oncol Clin North Am (2012) 0.80
Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget (2016) 0.80
Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio. J Clin Med Res (2016) 0.80
High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. J Hematol Oncol (2015) 0.80
Multiple myeloma: an update. Oman Med J (2013) 0.79
Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Front Immunol (2014) 0.79
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist (2016) 0.79
Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) magnetic resonance imaging as a biomarker for symptomatic multiple myeloma. PLoS One (2015) 0.79
Recent advances in understanding multiple myeloma. F1000Res (2016) 0.78
Development and Validation of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data. Front Oncol (2016) 0.78
Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Rev Hematol (2010) 0.78
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist (2011) 0.78
Steroid-resistant nephrotic syndrome secondary to primary focal segmental glomerulosclerosis and smoldering multiple myeloma. Proc (Bayl Univ Med Cent) (2014) 0.78
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia (2016) 0.77
Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. Cancer J (2009) 0.77
Multiple myeloma in the very elderly patient: challenges and solutions. Clin Interv Aging (2016) 0.76
Identify multiple myeloma stem cells: Utopia? World J Stem Cells (2015) 0.76
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. Leukemia (2016) 0.76
MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood (2016) 0.76
Myelomagenesis: capturing early microenvironment changes. Semin Hematol (2011) 0.75
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J (2016) 0.75
Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin (2016) 0.75
Recent advances in multiple myeloma: a Korean perspective. Korean J Intern Med (2016) 0.75
Smoldering multiple myeloma. N Engl J Med (2007) 0.75
Novel therapies delay the progression of smoldering multiple myeloma: Case report and discussion. Ecancermedicalscience (2010) 0.75
Challenges in multiple myeloma diagnosis and treatment. Leuk Suppl (2013) 0.75
Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature. Pulm Circ (2015) 0.75
Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol (2016) 0.75
The road to cure in multiple myeloma starts with smoldering disease. Expert Opin Orphan Drugs (2015) 0.75
Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma. J Transl Med (2016) 0.75
Smoldering multiple myeloma. N Engl J Med (2007) 0.75
Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapies. Clin Exp Immunol (2014) 0.75
Smoldering multiple myeloma. N Engl J Med (2007) 0.75
Robert Arthur Kyle, MD: a conversation with the editor. Proc (Bayl Univ Med Cent) (2010) 0.75
Solitary bone plasmacytoma progressing into retroperitoneal plasma cell myeloma with no related end organ or tissue impairment: a case report and review of the literature. Turk J Haematol (2014) 0.75
Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials. PLoS One (2014) 0.75
Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci (2016) 0.75
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Multiple myeloma. N Engl J Med (2004) 10.81
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 6.98
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67
Multiple myeloma. Blood (2008) 5.88
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol (2009) 5.73
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
Meckel diverticulum: the Mayo Clinic experience with 1476 patients (1950-2002). Ann Surg (2005) 4.72
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 3.88
Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum (2010) 3.84
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood (2011) 3.58
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol (2009) 3.42
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol (2005) 3.41
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood (2002) 3.34
Association of Clinical Researchers and Educators a statement on relationships between physicians and industry. Endocr Pract (2012) 3.27
Significant reduction in risk of falls and back pain in osteoporotic-kyphotic women through a Spinal Proprioceptive Extension Exercise Dynamic (SPEED) program. Mayo Clin Proc (2005) 3.26
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging (2010) 3.03
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Surgical treatment of appendiceal mucocele. Arch Surg (2003) 2.74
Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol (2011) 2.74
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol (2003) 2.72
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood (2003) 2.68